Our next journal club features two papers on the topic of Survival Analysis. The webinar will be held on the 24th March 2021 from 4-5pm GMT.
Please click here to view the flyer.
REGISTER HERE: https://attendee.gotowebinar.com/register/666145030521313291
The journal club gives a forum to participate and listen to discussion on different topics.
Who is this event intended for? Anyone with an interest in Survival Analysis including discussions on sample size calculations, non-parametric survival comparisons and methods allowing for delayed treatment effects.
What is the benefit of attending? People should attend to learn more about the different techniques and applications of survival analysis methods for delayed treatment effects and non-proportional hazards.
Please join us to hear Dominic Magirr (Novartis) and Chang Yu (Vanderbilt University) present their recent work. The webinar will be chaired by Jennifer Rogers (PHASTAR).
Dominic Magirr (Novartis):- Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?
Authors: Dominic Magirr
Pharmaceutical Statistics. 20 20;1-16
Chang Yu (Vanderbilt University):- A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect
Authors: Chang Yu, Xiang Huang, Hui Nian and Philip He Pharmaceutical Statistics. 20 21;1– 23
For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
The meetings are open to both PSI and non-PSI members.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
At this meeting we will present the evolution of missing data approaches, looking at how they have been handled in the past, the current established missing data approaches and the impact of the new ICH E9 R1 addendum on the handling of missing data, focussing in particular on the treatment policy estimand.
R is quickly gaining popularity within the pharmaceutical industry due to it being a very powerful object-orientated language, and is able to produce analyses and high quality graphics. This will be a hands-on interactive course and will utilise the RStudio Cloud development environment.
The format of this event will include Ted Talks by all of our speakers with the opportunity for us to have a discussion together after each of the presentations.
A year on after the final ICH E9 estimands addendum was published, we bring estimands to life. Members of the Estimands in Oncology special interest group will describe how the estimand framework provides a common language to describe the diversity of patient journeys and why it is important to address the right question in clinical trials.
This course will cover the essentials of DMC set up (roles and responsibilities, DMC charter, practical considerations), as well as discussing DMC case studies and the role of DMCs in adaptive trials and during the pandemic. In addition, there will be an interactive DMC workshop.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.
This position provides expert statistical input and project management for statistical activities in relation to clinical trials and statistical activities executed by the Consumer Healthcare division
